-
Valeant to acquire Eyetech
MISSISSAUGA, Ontario — Valeant Pharmaceuticals is set to acquire a privately owned ophthalmic biotechnology company, the drug maker said Monday.
Valeant said it will acquire Eyetech upfront payment and potential future milestones. The transaction, which is subject to customary closing conditions, is expected to close this week. Additional details were not disclosed.
-
Bydureon officially hits market
SAN DIEGO — Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.
Bydureon (exenatide extended-release for injectable suspension) received approval from the Food and Drug Administration on Jan. 27 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.